Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Moon rocket and weather are on NASA's side for the first astronaut launch in decades - 2People are getting their news from AI – and it’s altering their views
- 3Scientists discover black hole flare with the light of 10 trillion suns
- 4Russian drone slams into block of flats in deadly wave of strikes across Kyiv
- 5Israeli girl suffers cardiac arrest during sirens in Safed, hospitalized in serious condition
- As nations push for more ambition at climate talks, chairman says they may get it
- Ukrainian man arrested in Germany on suspicion of spying for Russia
- Old food pyramid vs. RFK Jr.'s new food pyramid. See what's different.
- How does spider venom damage human cells? Researchers uncover the killer mechanism of recluse spider toxin
- 'Here we go again': Businesses grapple with fuel costs
- A 'Stranger Things' documentary covering the final season is on its way: Watch the trailer
- Mars orbiter sees 'butterfly' crater spread its wings on the Red Planet
- Jill Hennessy was a '90s TV staple. Now she's in her fearless era.
- 7 Odd Apparatuses to Make Your Party Stick Out!
